- Stocks
- Healthcare
- NASDAQ: CYCN

Price (delayed)

$3.72

Market cap

$126.98M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.23

Enterprise value

$130.51M

Cyclerion Therapeutics's EPS has increased by 42% YoY and by 13% from the previous quarter

The net income rose by 33% year-on-year and by 9% since the previous quarter

The revenue has dropped by 76% year-on-year and by 41% since the previous quarter

The company's gross profit has shrunk by 76% YoY and by 41% QoQ

What are the main financial stats of CYCN

Market
Valuations
Earnings

Shares outstanding

34.13M

Market cap

$126.98M

Enterprise value

$130.51M

Price to earnings (P/E)

N/A

Price to book (P/B)

2.62

Price to sales (P/S)

94.33

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

97.11

Revenue

$1.34M

EBIT

-$70.97M

EBITDA

-$69.04M

Free cash flow

-$54.93M

Per share
Balance sheet
Liquidity

EPS

-$2.23

Free cash flow per share

-$1.61

Book value per share

$1.42

Revenue per share

$0.04

TBVPS

$2.93

Total assets

$99.97M

Total liabilities

$51.53M

Debt

$44.96M

Equity

$48.43M

Working capital

$30.98M

Debt to equity

0.93

Current ratio

3.3

Quick ratio

3.08

Net debt/EBITDA

-0.05

Margins
Efficiency
Dividend

EBITDA margin

-5,137.2%

Gross margin

100%

Net margin

-5,280.7%

Operating margin

-5,354%

Return on assets

-59.8%

Return on equity

-113.8%

Return on invested capital

-74.1%

Return on capital employed

-82%

Return on sales

-5,280.7%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Cyclerion Therapeutics stock price performed over time

Intraday

1.09%

1 week

-6.3%

1 month

25.68%

1 year

-17.15%

YTD

21.57%

QTD

33.33%

How have Cyclerion Therapeutics's revenue and profit performed over time

Revenue

$1.34M

Gross profit

$1.34M

Operating income

-$71.96M

Net income

-$70.97M

Gross margin

100%

Net margin

-5,280.7%

Cyclerion Therapeutics's net margin has plunged by 175% YoY and by 56% from the previous quarter

Cyclerion Therapeutics's operating margin has plunged by 173% YoY and by 51% from the previous quarter

The revenue has dropped by 76% year-on-year and by 41% since the previous quarter

The company's gross profit has shrunk by 76% YoY and by 41% QoQ

What is Cyclerion Therapeutics's growth rate over time

What is Cyclerion Therapeutics stock price valuation

P/E

N/A

P/B

2.62

P/S

94.33

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

97.11

Cyclerion Therapeutics's EPS has increased by 42% YoY and by 13% from the previous quarter

The equity has contracted by 41% YoY and by 19% from the previous quarter

The stock's price to book (P/B) is 19% more than its last 4 quarters average of 2.2

CYCN's P/S is 88% above its last 4 quarters average of 50.1

The revenue has dropped by 76% year-on-year and by 41% since the previous quarter

How efficient is Cyclerion Therapeutics business performance

Cyclerion Therapeutics's ROS has plunged by 175% YoY and by 56% from the previous quarter

The company's return on equity fell by 18% YoY and by 3.3% QoQ

CYCN's return on assets is down by 9% year-on-year

The return on invested capital has increased by 6% year-on-year and by 3.8% since the previous quarter

What is CYCN's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CYCN.

How did Cyclerion Therapeutics financials performed over time

Cyclerion Therapeutics's total assets is 94% more than its total liabilities

The quick ratio has contracted by 48% YoY and by 4.3% from the previous quarter

The current ratio has decreased by 46% YoY and by 4.3% from the previous quarter

Cyclerion Therapeutics's debt is 7% less than its equity

Cyclerion Therapeutics's debt to equity has soared by 52% YoY and by 21% from the previous quarter

The equity has contracted by 41% YoY and by 19% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.